E6(R3): Beyond Compliance in Vendor Oversight

Introduction

The ICH E6(R3) Good Clinical Practice guideline is redefining vendor oversight in clinical trials. Oversight is no longer periodic—it must be continuous, risk-based, and fully traceable across vendors, studies, and services.

Why This Matters

Most pharma organizations still operate with fragmented systems, manual workflows, and limited visibility. This creates delays, weak traceability, and reactive risk management.

Key Challenges

• Risk is identified too late
• Decisions are difficult to justify
• KPIs do not drive action
• Systems are fragmented

What E6(R3) Requires

• Continuous monitoring of vendor risk
• Full decision traceability
• Structured governance across the lifecycle

From Management to Control

Organizations must shift to:

• Real-time visibility
• Integrated decision-making
• End-to-end traceability
• Operational orchestration

Role of Clinical Maestro Vision

Vision enables continuous monitoring, structured workflows, and governance at scale—turning vendor management into vendor control.

Conclusion

E6(R3) changes the question from 'Are you compliant?' to 'Can you prove it at scale?'

Call to Action

Join our webinar on 20 May 2026 to explore how to move from fragmented oversight to real-time control.